US Patent

US10952968 — Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives

Composition of Matter · Assigned to Shionogi and Co Ltd · Expires 2033-05-13 · 7y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a solid preparation that improves the dissolution profile and stability of a 6,7-unsaturated-7-carbamoyl morphinan derivative.

USPTO Abstract

The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.

Drugs covered by this patent

Patent Metadata

Patent number
US10952968
Jurisdiction
US
Classification
Composition of Matter
Expires
2033-05-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Shionogi and Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.